🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Finally out: new evidence for efficacy and safety of a #COVID19 booster vaccination in #Rituximab-treated patients. Thanks to all the authors! MedUni Wien @kim3_med Daniel Aletaha Leo Heinz Judith Aberle ard.bmj.com/content/early/…

PatientInnen, die eine immunsuppressive Therapie erhalten, haben auch nach zweimaliger #COVID19-#Schutzimpfung ein erhöhtes Risiko für schwere Krankheitsverläufe. Eine im @ard_bmj veröffentlichte Studie zeigt die Wirkung der #Boosterimpfung. ⬇️ bit.ly/3qZ43jW

Patients unter #immunosuppressiveTherapy, who do not respond to primary #COVID19Vaccination, have an increased risk for severe disease courses. A study by #MedUniVienna published in @ard_bmj shows the effect of a third vaccination. ⬇️ bit.ly/3IDecZr

📢Join the #grebienlab Vetmeduni! We are looking for a #postdoc to work on #genetic determinants of #drug response and resistance in #leukemia. #CRISPR screening➕mouse models➕patient cells➕large datasets➡️new #mechanisms➕#biomarkers. RT/DM! 👉grebienlab.com/postdoc-positi…

Rituximab and 4th COVID-19 vaccination: Continuation of rituximab impaires "boostability". Thanks to our fantastic coautors! #COVID19 #Booster #rituximab ard.bmj.com/content/early/…

What is the effect of vaccination against #SARSCOV2 for a fourth time in #Rituximab patients with #RMD ▶️seroconversion in 58% ▶️Seroconversion and antibody increase were ↘️ in those received rituximab between the 3# and the 4# bit.ly/3c8nK4f

Very happy to share the first manuscript of our lab Department of Immunobiology at UNIL Faculté de biologie et de médecine (inactif) now on Biorxiv! SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL. biorxiv.org/content/10.110…

For our new lab in Berlin we are looking for a motivated technician who wants to do cutting edge research in autoimmunity with us 👩‍🔬🧑‍🔬! Please apply 😃karriere.charite.de/stellenangebot…

We are hiring! We are also looking for two enthusiastic PhD students to join our team 😃

New insights into T cell - fibroblast interactions and development of synovial pathotypes in #RA patients. Thanks to all coauthors! ard.bmj.com/content/early/…

📣We are recruiting a bioinformatician with an interest in Immunology who will collaborate closely with researchers & clinicians from the whole division. 🤝 Please share the word if you know anyone in your network that could match this profile! tinyurl.com/5aah6p6b

2 x SLC15A4-TASL Nature Communications! Check out our latest collaboration with Giulio Superti-Furga Superti-Furga Lab and Leo Heinz. After discovering the TASL-SLC15A4 complex 3 years ago, we designed a screening assay monitoring its assembly and identified the inhibitor C5 1/4 nature.com/articles/s4146…

In a new Nature Communications study led by Giulio Superti-Furga, scientists for the first time identified and characterized a new small molecule called "Feeblin", which can inhibit the interaction of #SLC15A4 with #TASL. This could help patients with systemic lupus. #SLE ➡️ bit.ly/3PWIFag

🤩All you want to know about #JAKinhibitors is in this #review❗ ⛳ #efficacy 🛡️ #safety 🎯 #selectivity 🔢 1^/2^#generation 👉 new paradigm for the treatment of #inflammatorydiseases #RA #PsA #SpA #psoriasis #IBD #AD 🔗bit.ly/3QKL2Pa Daniel Aletaha Bonelli Lab

What is the right primary endpoint for RA clinical trials? ACR20? 50? 70? Two researchers from our group, Victoria Konzett and Andreas Kerschbaumer drew a comprehensive conclusion for superiority assessment of placebo-controlled RA trials.👉 ard.bmj.com/content/early/…

Collaboration between Superti-Furga Lab, RebsamenLab and Leo Heinz identified feeblin, an inhibitory compound of the pro-inflammatory TLR7/8/9-IRF5 pathway which disrupts the SLC15A4-TASL interaction. nature.com/articles/s4146…

We are hiring a PhD student in the field of autoimmunity, please share!

Future opportunities in solute carrier structural biology nature.com/articles/s4159…